Race releases cardioprotection market potential data

<ul>

<li class="typography-body-regular"><strong>Triangle Insights conducted blinded primary research with stakeholders to investigate Zantrene’s commercial potential as cardio-protective and anti-cancer agent within key cancer types where anthracyclines are typically used</strong></li>

<li class="typography-body-regular"><strong>Assessment suggests that Zantrene is well-positioned for use in metastatic breast cancer broadly, and within the neoadjuvant setting for HR+/HER2- and triple negative breast cancer (HR-/HER2), relative to the profile assessed</strong></li>

<li class="typography-body-regular"><strong>Significant opportunity: may offer &gt;$5B USD if anti-cancer efficacy is demonstrated, or ~$1B USD as a supportive care cardio-protective therapeutic</strong></li>

</ul>